Form 8-K - Current report:
SEC Accession No. 0001628280-25-000005
Filing Date
2025-01-02
Accepted
2025-01-02 07:04:39
Documents
16
Period of Report
2025-01-01
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K avtx-20250101.htm   iXBRL 8-K 37524
2 EX-10.1 ex-101employmentagreementx.htm EX-10.1 95807
3 EX-99.1 ex-991csoappointment.htm EX-99.1 19514
7 GRAPHIC avalologoa.jpg GRAPHIC 8535
  Complete submission text file 0001628280-25-000005.txt   314125

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avtx-20250101.xsd EX-101.SCH 1850
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avtx-20250101_lab.xml EX-101.LAB 21026
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avtx-20250101_pre.xml EX-101.PRE 12041
18 EXTRACTED XBRL INSTANCE DOCUMENT avtx-20250101_htm.xml XML 2625
Mailing Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850
Business Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

EIN.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37590 | Film No.: 25500208
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)